The FDA announced plans to strengthen its Risk Evaluation and Mitigation Strategies (REMS) program for transmucosal immediate-release fentanyl (TIRF) products “to help ensure that the benefits of these drugs continue to outweigh the risks,” according to a statement by an agency official.